Back to top
more

Sarepta Therapeutics (SRPT)

(Delayed Data from NSDQ)

$131.82 USD

131.82
735,572

-0.48 (-0.36%)

Updated May 10, 2024 04:00 PM ET

After-Market: $131.94 +0.12 (0.09%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (84 out of 251)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

REGENXBIO (RGNX) Soars 15% on Interim Data From DMD Study

Data from an early-stage study shows that treatment with REGENXBIO's (RGNX) investigational Duchenne therapy RGX-202 demonstrates early evidence of strength and motor function improvement.

Sarepta (SRPT) Q4 Earnings Beat Estimates, Revenues Up Y/Y

Sarepta's (SRPT) Q4 earnings and sales beat estimates on the back of strong sales for recently-approved DMD gene therapy Elevidys.

Sarepta Therapeutics (SRPT) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

The headline numbers for Sarepta Therapeutics (SRPT) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

CytomX (CTMX) to Report Q4 Earnings: Here's What to Expect

Investor focus is likely to be on CytomX Therapeutics' (CTMX) updates on key cancer immunotherapeutic candidates, CX-904 and BMS-986288, on the fourth-quarter 2023 earnings call.

Puma Biotechnology (PBYI) to Report Q4 Earnings: What's in Store?

On Puma Biotechnology's (PBYI) fourth-quarter 2023 earnings call, investors' focus is likely to be on the sales performance of its sole marketed cancer drug, Nerlynx.

Why Earnings Season Could Be Great for Sarepta Therapeutics (SRPT)

Sarepta Therapeutics (SRPT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Avalo (AVTX) to Report Q4 Earnings: What's in the Cards?

Devoid of marketed drugs, investors will focus on Avalo Therapeutics' (AVTX) lead pipeline drug when it reports fourth-quarter earnings results.

Fusion (FUSN) to Report Q4 Earnings: Here's What to Expect

Investor focus is likely to be on updates regarding Fusion Pharmaceuticals' (FUSN) pipeline candidates on the fourth-quarter conference call.

Ginkgo (DNA) to Report Q4 Earnings: What's in the Cards?

On Ginkgo's (DNA) fourth-quarter earnings call, investor focus is likely to be on the sales performance of its two business units, Biosecurity and Cell Engineering.

Eton Pharma (ETON) to Report Q4 Earnings: What's in the Cards?

Eton Pharma's (ETON) revenues in the fourth quarter of 2023 are expected to have been driven by the sales of its marketed products.

The Zacks Analyst Blog Highlights Moderna, RAPT Therapeutics, Iovance, Sarepta Therapeutics and Regeneron

Moderna, RAPT Therapeutics, Iovance, Sarepta Therapeutics and Regeneron are included in this Analyst Blog.

Biotech Stock Roundup: MRNA's Q4 Results, RAPT Down on Study Results & Other Updates

Earnings from Moderna (MRNA) and pipeline update from RAPT are in focus in the biotech sector.

Sarepta (SRPT) to Report Q4 Earnings: Will It Beat Estimates?

Investors' focus will likely be on Sarepta's (SRPT) product sales of its recently-approved DMD gene therapy when it reports fourth-quarter earnings.

Aquestive (AQST) to Report Q4 Earnings: Here's What to Expect

Investor focus is likely to be on Aquestive Therapeutics' (AQST) updates regarding key pipeline candidate, Anaphylm Sublingual Film, on the fourth-quarter 2023 earnings call.

Repligen (RGEN) Lags Q4 Earnings and Revenue Estimates

Repligen (RGEN) delivered earnings and revenue surprises of -2.94% and 0.11%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Amphastar (AMPH) to Report Q4 Earnings: What's in the Cards?

Amphastar's (AMPH) revenues in the fourth quarter of 2023 are expected to have been driven by the sales of its pharmaceutical products.

Perrigo (PRGO) to Report Q4 Earnings: What's in the Cards?

Perrigo's (PRGO) new products and products added through acquisitions are expected to have aided the top line in the soon-to-be-reported quarter.

BeiGene (BGNE) to Report Q4 Earnings: What's in the Cards?

BeiGene's (BGNE) revenues in fourth-quarter 2023 are expected to have been driven by the sales of its marketed pharmaceutical products.

Altimmune (ALT) to Report Q4 Earnings: What's in the Cards?

On Altimmune's (ALT) fourth-quarter 2023 earnings call, investors' focus is likely to be on the company's progress with the development of its lead pipeline candidate, pemvidutide.

Sarepta Therapeutics (SRPT) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

Sarepta Therapeutics (SRPT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Bayer (BAYRY) Intends to Slash Dividends Amid Challenges

Bayer (BAYRY) announced plans to cut dividends to pay out only the legally required minimum for three years in the wake of high debt and increasing legal costs.

Can Rigel Pharmaceuticals (RIGL) Beat Q4 Earnings Estimates?

Rigel Pharmaceuticals' (RIGL) Tavalisse tablet sales are expected to have risen in the fourth quarter, driven by demand growth.

Sarepta's (SRPT) DMD Drug sBLA Gets FDA's Priority Tag, Stock Up

Sarepta (SRPT) announces the FDA's acceptance of its efficacy supplement to the Elevidys BLA, seeking to expand the treatment label for its DMD drug. The stock gains 8%.

Sarepta Therapeutics (SRPT) Moves 7.8% Higher: Will This Strength Last?

Sarepta Therapeutics (SRPT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.